Company intelligence / Profile preview
GenVivo
San Marino, California, United Statesgenvivoinc.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Phase 1
01
Overview
GenVivo’s lead candidate GEN2 has entered Phase 1 trials for cancer. It uses a proprietary HSV-eTK gene and GM-CSF to induce tumor cell death and stimulate immune response. Other programs are at preclinical or IND-enabling stages. Rexin-G was previously approved in the Philippines for solid tumors.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Gene therapy (viral vectors)immunotherapy (cytokine gene delivery)biological products
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Not specified in public sources.
Beyond the preview
Go deeper on GenVivo.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GenVivo.